…
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tilray Brands Inc. is a multinational company that produces and distributes medical and adult-use cannabis, hemp-derived products and related consumer packaged goods across several markets. Long-term growth drivers include expanding legalization and medical adoption, international market expansion, and product and brand diversification that may support revenue growth and margin improvement. Investors may find the company attractive for its scale and diversified product portfolio and established distribution footprint.
Key risks include regulatory uncertainty in major markets (notably U.S. federal prohibition), ongoing industry pricing and competitive pressures, and the need to deliver sustained profitability while managing financing and integration risks.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Income before tax | -2302.37M | -249.02M | -1450.18M | -440.67M | -344.99M |
| Minority interest | -5.38M | -22.58M | -9.66M | -42.67M | 6.24M |
| Net income | -2186.74M | -244.98M | -1443.00M | -434.13M | -336.01M |
| Selling general administrative | 166.40M | 171.56M | 230.94M | 162.80M | 111.58M |
| Selling and marketing expenses | 93.09M | 79.17M | - | 65.86M | 44.12M |
| Gross profit | 240.57M | 223.35M | 146.96M | 116.82M | 123.18M |
| Reconciled depreciation | 133.49M | 126.91M | 130.15M | 115.19M | 67.83M |
| Ebit | -2261.04M | -199.76M | - | 153.29M | -4.95M |
| Ebitda | -2127.55M | -72.84M | -1306.44M | 268.49M | 30.27M |
| Depreciation and amortization | 133.49M | 126.91M | - | 115.19M | 35.22M |
| Operating income | -2282.70M | -174.75M | -178.15M | 153.29M | -4.95M |
| Other operating expenses | 3104.01M | 963.69M | - | 856.92M | 581.64M |
| Interest expense | 41.33M | 49.26M | 13.59M | 39.68M | 30.90M |
| Tax provision | -121.02M | -26.62M | -7.18M | -6.54M | -5.60M |
| Interest income | 11.38M | 12.83M | 33.02M | 11.74M | 26.05M |
| Net interest income | -29.95M | -36.43M | -13.59M | -27.94M | -27.98M |
| Income tax expense | -121.02M | -26.62M | - | -6.54M | -8.97M |
| Total revenue | 821.31M | 788.94M | 627.12M | 628.37M | 513.09M |
| Total operating expenses | 2523.28M | 398.10M | 805.27M | 345.37M | 191.74M |
| Cost of revenue | 580.74M | 565.59M | 480.16M | 511.56M | 389.90M |
| Total other income expense net | -19.67M | -74.28M | -1258.45M | -593.97M | -340.04M |
| Net income from continuing ops | -2181.36M | -222.40M | -1443.00M | -434.13M | -336.01M |
| Net income applicable to common shares | - | - | - | -476.80M | -367.42M |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Total assets | 2074.33M | 4221.66M | 4307.26M | 5449.69M | 6025.36M |
| Intangible assets | 21.42M | 915.47M | 973.78M | 1277.88M | 1605.92M |
| Other current assets | 34.09M | 31.33M | 37.72M | 46.79M | 48.92M |
| Total liab | 584.75M | 778.49M | 977.32M | 1008.33M | 1560.05M |
| Total stockholder equity | 1511.47M | 3442.91M | 3315.69M | 4398.81M | 4459.07M |
| Other current liab | 16.09M | 18.25M | 18.04M | 119.09M | 293.93M |
| Common stock | - | 0.08M | - | 0.05M | 0.05M |
| Capital stock | 0.11M | 0.08M | 0.07M | 0.05M | 0.05M |
| Retained earnings | -4847.23M | -2660.49M | -2415.51M | -962.85M | -486.05M |
| Other liab | - | - | - | 196.83M | 269.75M |
| Good will | 752.35M | 2008.88M | 2008.84M | 2641.30M | 2832.79M |
| Other assets | - | - | - | 111.51M | 8.29M |
| Cash | 221.67M | 228.34M | 206.63M | 415.91M | 488.47M |
| Total current liabilities | 280.30M | 299.17M | 432.98M | 280.34M | 401.24M |
| Current deferred revenue | - | 136.56M | - | - | 155.11M |
| Net debt | 35.20M | 158.98M | 373.14M | 207.90M | 450.19M |
| Short term debt | - | 38.96M | - | 92.65M | 49.60M |
| Short long term debt | 21.95M | 33.87M | 221.84M | 85.95M | 45.34M |
| Short long term debt total | - | 387.32M | - | 623.81M | 938.66M |
| Other stockholder equity | - | 6146.81M | - | 5382.37M | 4792.41M |
| Property plant equipment | - | - | - | 600.50M | 668.97M |
| Total current assets | 688.63M | 677.71M | 773.03M | 803.50M | 883.61M |
| Long term investments | 10.13M | 7.86M | 12.37M | 15.00M | 25.79M |
| Net tangible assets | - | - | - | 479.62M | 20.36M |
| Short term investments | 34.70M | 32.18M | 241.90M | - | - |
| Net receivables | 121.49M | 101.69M | 86.23M | 95.28M | 89.79M |
| Long term debt | 234.92M | 287.94M | 357.93M | 519.83M | 306.26M |
| Inventory | 270.88M | 252.09M | 200.55M | 245.53M | 256.43M |
| Accounts payable | 107.35M | 105.39M | 70.82M | 68.60M | 57.71M |
| Accumulated other comprehensive income | - | -43.50M | - | -20.76M | 152.67M |
| Non currrent assets other | 11.08M | 5.39M | 0.22M | 111.51M | 8.29M |
| Non current assets total | 1385.70M | 3543.95M | 3534.23M | 4646.19M | 5141.75M |
| Capital lease obligations | 71.87M | 65.51M | 10.36M | 18.03M | 58.21M |
| Long term debt total | - | - | - | - | 870.59M |
| Breakdown | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 |
| Investments | -46.72M | 128.35M | -285.11M | -21.53M | 8.43M |
| Change to liabilities | - | - | - | -44.65M | 14.63M |
| Total cashflows from investing activities | -46.72M | 128.35M | - | -21.53M | 46.10M |
| Net borrowings | -26.14M | -83.81M | - | -123.55M | 45.51M |
| Total cash from financing activities | 133.51M | -75.19M | 70.16M | 128.20M | 124.31M |
| Change to operating activities | - | - | - | 4.47M | -6.77M |
| Net income | -2181.36M | -222.40M | -1443.00M | -434.13M | -336.01M |
| Change in cash | -6.67M | 21.71M | -209.28M | -72.56M | 127.82M |
| Begin period cash flow | 228.34M | 206.63M | 415.91M | 488.47M | 360.65M |
| End period cash flow | 221.67M | 228.34M | 206.63M | 415.91M | 488.47M |
| Total cash from operating activities | -94.60M | -30.91M | 7.91M | -177.26M | -44.72M |
| Issuance of capital stock | 161.19M | 8.62M | 129.59M | 262.51M | 102.55M |
| Depreciation | 133.49M | 126.91M | 130.15M | 154.59M | 67.83M |
| Other cashflows from investing activities | 4.31M | 209.72M | - | - | 3.33M |
| Change to inventory | -13.56M | -15.58M | -12.93M | -45.75M | -35.29M |
| Change to account receivables | -17.80M | -6.58M | 4.17M | -5.84M | -23.51M |
| Sale purchase of stock | 0.00M | 0.00M | -1.19M | - | 220.20M |
| Other cashflows from financing activities | -1.54M | -2.90M | - | -1.36M | 87.38M |
| Change to netincome | - | - | - | 236.72M | 325.73M |
| Capital expenditures | 32.92M | 29.25M | 20.80M | 34.06M | 38.87M |
| Change in working capital | -62.56M | -8.87M | 14.40M | -91.77M | -50.94M |
| Stock based compensation | 24.29M | 31.77M | 39.59M | 35.99M | 17.35M |
| Other non cash items | 2112.56M | 80.56M | 258.59M | 185.59M | 281.92M |
| Free cash flow | -127.52M | -60.15M | -12.89M | -211.33M | -83.59M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLRY Tilray Inc |
0.39 10.48% |
4.11 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.30 |
| CURA Curaleaf Holdings Inc. |
-1.03 7.24% |
13.20 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.39 3.42% |
11.80 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| CRON Cronos Group Inc |
0.11 2.31% |
4.87 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| GUD Knight Therapeutics Inc. |
-0.06 0.53% |
11.20 | - | 48.54 | 1.64 | 0.96 | 1.60 | 11.97 |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Irwin David Simon | Pres, CEO & Chairman | 1958 |
| Mr. Carl A. Merton CA, CBV, CPA | CFO & Principal Accounting Officer | 1970 |
| Mr. Mitchell S. Gendel | Global Gen. Counsel & Corp. Sec. | 1966 |
| Mr. James R. Meiers | Sr. VP of U.S. Operations | 1958 |
| Ms. Denise Menikheim Faltischek | Chief Strategy Officer & Head of International | 1973 |
| Mr. Lloyd Brathwaite | Chief Information Officer | NA |
| Mr. Roger Savell | Chief Admin. Officer | NA |
| Mr. John B. Sadler | VP of Investor Relations | NA |
| Ms. Dara S. Redler | Interim Chief Legal Officer & Corp. Sec. | NA |
| Mr. Bernard Yeung | Sr. VP of Sales & Marketing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.